The administration of a loading dose of aspirin to patients presenting with acute myocardial infarction while receiving chronic aspirin treatment reduces thromboxane A₂-dependent platelet reactivity

References

• Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007;357:2482–2494
   PubMed Web of Science ®Google Scholar
• Santos MT, Valles J, Marcus AJ, Safier LB, Broekman MJ, Islam N, Ullman HL, Eiroa AM, Aznar J. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. J Clin Invest 1991;87:571–580
   PubMed Web of Science ®Google Scholar
• Valles J, Santos MT, Aznar J, Marcus AJ, Martinez-Sales V, Portoles M, Broekman MJ, Safier LB. Erythrocytes metabolically enhance collagen-induced platelet responsiveness via increased thromboxane production, adenosine diphosphate release, and recruitment. Blood 1991;78:154–162
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists C. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71–86
   PubMed Web of Science ®Google Scholar
• Snoep JD, Hovens MMC, Eikenboom JCJ, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: A systematic review and meta-analysis. Arch Intern Med 2007;167:1593–1599
   PubMed Web of Science ®Google Scholar
• Crescente M, Di Castelnuovo A, Lacoviello L, de Gaetano G, Cerletti C. PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: A meta-analysis of 19 studies comprising 3003 patients. Thromb Haemost 2008;99:1129–1131
   PubMedGoogle Scholar
• Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin “resistance” and risk of cardiovascular morbidity: Systematic review and meta-analysis. BMJ 2008;336:195–198
   PubMed Web of Science ®Google Scholar
• Sofi F, Marcucci R, Gori AM, Abbate R, Gensini GF. Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events–a meta-analysis. Int J Cardiol 2008;128:166–171
   PubMed Web of Science ®Google Scholar
• Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: The relationships among dose, effectiveness, and side effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:234S–264S
   PubMed Web of Science ®Google Scholar
• Cattaneo M. Aspirin and clopidogrel: Efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004;24:1980–1987
   PubMed Web of Science ®Google Scholar
• Michelson AD. Methods for the measurement of platelet function. Am J Cardiol 2009;103:20A–26A
   PubMed Web of Science ®Google Scholar
• Aradi D, Komocsi A, Vorobcsuk A, Rideg O, Tokes-Fuzesi M, Magyarlaki T, Horvath IG, Serebruany VL. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: Systematic review and meta-analysis. Am Heart J 2010;160:543–551
   PubMed Web of Science ®Google Scholar
• Valles J, Santos MT, Fuset MP, Moscardo A, Ruano M, Perez F, Piñon M, Breña S, Aznar J. Partial inhibition of platelet thromboxane A2 synthesis by aspirin is associated with myonecrosis in patients with ST-segment elevation myocardial infarction. Am J Cardiol 2007;99:19–25
   PubMed Web of Science ®Google Scholar
• Santos MT, Fuset MP, Ruano M, Moscardo A, Valles J. Effect of atorvastatin on platelet thromboxane A(2) synthesis in aspirin-treated patients with acute myocardial infarction. Am J Cardiol 2009;104:1618–1623
   PubMedGoogle Scholar
• Moscardo A, Santos MT, Fuset MP, Ruano M, Valles J. Residual cyclooxygenase-1 activity and epinephrine reduce the antiplatelet effect of aspirin in patients with acute myocardial infarction. Thromb Haemost 2011;105:663–669
   PubMed Web of Science ®Google Scholar
• Fuchs I, Spiel AO, Frossard M, Derhaschnig U, Riedmuller E, Jilma B. Platelet hyperfunction is decreased by additional aspirin loading in patients presenting with myocardial infarction on daily aspirin therapy. Crit Care Med 2010;38:1423–1429
   PubMed Web of Science ®Google Scholar
• Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999–3054
   PubMed Web of Science ®Google Scholar
• Valles J, Santos MT, Aznar J, Osa A, Lago A, Cosin J, Sanchez E, Broekman MJ, Marcus AJ. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: The effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation 1998;97:350–355
   PubMed Web of Science ®Google Scholar
• Santos MT, Valles J, Lago A, Tembl J, Sanchez E, Moscardo A, Cosin J. Residual platelet thromboxane A2 and prothrombotic effects of erythrocytes are important determinants of aspirin resistance in patients with vascular disease. J Thromb Haemost 2008;6:615–621
   PubMed Web of Science ®Google Scholar
• Hamberg M, Svensson J, Samuelsson B. Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975;72:2994–2998
   PubMed Web of Science ®Google Scholar
• Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: Implications for therapy with platelet inhibitory drugs. Blood 1987;69:180–186
   PubMed Web of Science ®Google Scholar
• Smith JP, Haddad EV, Taylor MB, Oram D, Blakemore D, Chen Q, Boutaud O, Oates JA. Suboptimal inhibition of platelet cyclooxygenase-1 by aspirin in metabolic syndrome. Hypertension 2012;59:719–725
   PubMed Web of Science ®Google Scholar
• Homoncik M, Jilma B, Hergovich N, Stohlawetz P, Panzer S, Speiser W. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100 (R). Thromb Haemost 2000;83:316–321
   PubMed Web of Science ®Google Scholar
• Braunwald E. Biomarkers in heart failure. N Engl J Med 2008;358:2148–2159
   PubMed Web of Science ®Google Scholar
• Di Minno G, Silver MJ, Murphy S. Monitoring the entry of new platelets into the circulation after ingestion of aspirin. Blood 1983;61:1081–1085
   PubMed Web of Science ®Google Scholar
• Rocca B, Secchiero P, Ciabattoni G, Ranelletti FO, Catani L, Guidotti L, Melloni E, Maggiano N, Zauli G, Patrono C. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA 2002;99:7634–7639
   PubMed Web of Science ®Google Scholar
• Grove EL, Hvas AM, Kristensen SD. Immature platelets in patients with acute coronary syndromes. Thromb Haemost 2009;101:151–156
   PubMed Web of Science ®Google Scholar
• Cornelissen J, Kirtland S, Lim E, Goddard M, Bellm S, Sheridan K, Large S, Vuylsteke A. Biological efficacy of low against medium dose aspirin regimen after coronary surgery: Analysis of platelet function. Thromb Haemost 2006;95:476–482
   PubMed Web of Science ®Google Scholar
• Weyrich AS, Schwertz H, Kraiss LW, Zimmerman GA. Protein synthesis by platelets: Historical and new perspectives. J Thromb Haemost 2009;7:241–246
   PubMed Web of Science ®Google Scholar
• Evangelista V, Manarini S, Di Santo A, Capone ML, Ricciotti E, Di Francesco L, Tacconelli S, Sacchetti A, D'Angelo S, Scilimati A, et al. De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. Circ Res 2006;98:593–595
   PubMed Web of Science ®Google Scholar
• Reilly SJ, Li N, Liska J, Ekstrom M, Tornvall P. Coronary artery bypass graft surgery up-regulates genes involved in platelet aggregation. J Thromb Haemost 2012;10:557–563
   Google Scholar
• Cambria-Kiely JA, Gandhi PJ. Aspirin resistance and genetic polymorphisms. J Thromb Thrombolysis 2002;14:51–58
   PubMedGoogle Scholar
• Ellis EF, Oelz O, Roberts LJ, 2nd, Payne NA, Sweetman BJ, Nies AS, Oates JA. Coronary arterial smooth muscle contraction by a substance released from platelets: Evidence that it is thromboxane A2. Science 1976;193:1135–1137
   PubMed Web of Science ®Google Scholar
• Schror K. Thromboxane A2 and platelets as mediators of coronary arterial vasoconstriction in myocardial ischaemia. Eur Heart J 1990;11:27–34
   Google Scholar
• Willerson JT, Eidt JF, McNatt J, Yao SK, Golino P, Anderson HV, Buja LM. Role of thromboxane and serotonin as mediators in the development of spontaneous alterations in coronary blood flow and neointimal proliferation in canine models with chronic coronary artery stenoses and endothelial injury. J Am Coll Cardiol 1991;17:101B–110B
   Google Scholar
• Meyer B, Huelsmann M, Wexberg P, Delle Karth G, Berger R, Moertl D, Szekeres T, Pacher R, Heinz G. N-terminal pro-B-type natriuretic peptide is an independent predictor of outcome in an unselected cohort of critically ill patients. Crit Care Med 2007;35:2268–2273
   PubMed Web of Science ®Google Scholar
• Omland T, Persson A, Ng L, O'Brien R, Karlsson T, Herlitz J, Hartford M, Caidahl K. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002;106:2913–2918
   PubMed Web of Science ®Google Scholar
• Richards AM, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW, Elliott J, Frampton C, Turner J, Crozier IG, Yandle TG. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003;107:2786–2792
   PubMed Web of Science ®Google Scholar